FDA Panel To Weigh Relevance Of Liraglutide’s Diabetes Experience In Obesity
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will ask external advisors Sept. 11 how the GLP-1 agonist’s safety in type 2 diabetes, approved as Victoza in 2010, informs the safety profile in obesity, where Novo Nordisk is seeking a higher dose and a different name.